Newsroom

Systemic Treatment Administration [News]

Published On: August 13, 2018

In June 2018, Cancer Care Ontario (CCO) became aware of an issue relating to the administration of three systemic treatment drugs (Pembrolizumab, Nivolumab and Panitumumab) used to treat locally and advanced and metastatic cancers, where amounts of the drug remained in the IV tubing resulting in a reduction in intended dose delivery to some patients.